Publications by authors named "Aitova L"
Article Synopsis
- The study examines hospital records of Crohn's disease patients over six years to understand patterns in emergency admissions, surgical needs, and lesion locations.
- It includes a thorough analysis of surgical cases, clinical data, and the time taken from symptoms to diagnosis.
- Findings suggest that longer diagnostic delays can lead to more complications and a higher likelihood of needing surgery for these patients.
Laparoscopic cholecystectomy has many advantages over open surgery. Nevertheless, incidence of intraoperative bile duct injury is consistently higher for laparoscopic technique. This review is devoted to modern principles of identifying the anatomical elements in hepatoduodenal ligament and rules for safe tissue dissection in this area.
View Article and Find Full Text PDFObjective: To analyze treatment outcomes in patients with severe pseudomembranous colitis and previous coronavirus infection.
Material And Methods: We retrospectively analyzed treatment outcomes, clinical, laboratory and histological data in convalescents of COVID-19 who admitted to the department of coloproctology for moderate-to-severe pseudomembranous colitis confirmed by endoscopic examination between 2020 and 2021.
Results: There were 13 patients with moderate pseudomembranous colitis and 6 ones with severe pseudomembranous colitis.
Objective: To identify a correlation between diagnostic markers of Crohn's disease and endoscopic data using the Capsule Endoscopy Crohn's Disease Activity Index for isolated small intestine lesions.
Material And Methods: We studied 127 patients over previous 19 years. All patients were divided into 2 groups: isolated Crohn's disease of small intestine (group 1) and lesion of small and large intestine or large intestine only (group 2).
Aim: To evaluate efficacy of the protocol NHL BFM-90 in the treatment of adult anaplastic large cell lymphosarcoma (ALCL) ALK+ and validity of addition of transplantation of autologous stem hemopoietic cells (ASHC) into first line treatment.
Material And Methods: We treated 13 patients with stage III-IV ALCL ALK+. The age of the patients ranged from 17 to 44 years (median 26 years).